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Abstract 
Radionuclides have been widely used for cancer treatment. Recently, new research about radium-223 dichloride has 
been conducted in prostate cancer, which reveals that it is the first radiopharmaceutical to demonstrate an 
improvement in overall survival and time to first symptomatic skeletal event in patients with castration resistant 
prostate cancer with symptomatic bone metastases. This fact has created a new paradigm in the treatment of prostate 
cancer landscape, where only chemotherapy and hormone therapy had a role, while β-emitters had been confined 
exclusively to the role of pain relief with no impact on survival. The aim of this review is to outline current treatment 
approaches for advanced prostate cancer with a focus on the role of radium-223 dichloride, reviewing patients' profile 
that make them suitable to therapy and chances for further studies. 
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The skeleton is the most common organ to be affected by metastatic cancer, and prostate tumors have 
a special propensity to spread to the bone [1]. Most patients developing castration-resistant prostate 
cancer (CRPC) present radiographic evidences of bone metastases and related severe pain, neurological 
symptoms, pathological bone fractures, hypercalcemia, spinal cord compression or pancytopenia [2]. 
These symptoms induce a considerable impact on quality of life due to suffering, reduced functional 
capacity and increased non-self-sufficiency [3,4]. Skeletal metastases from prostate cancer are 
predominantly bone forming or osteoblastic lesions, although osteolytic lesions have also been reported 
[3]. Prostate cancer cells stimulate osteoblastic proliferation to produce specific growth factors for 
osteoblasts, which results in increased bone matrix deposition in the bone and tumor microenvironment 
[3]. Current treatments for bone metastases in CRPC patients include systemic chemotherapy, hormonal 
therapies, radium-223 dichloride (Ra-223) and other bone-targeted therapies. Others, including external-
beam radiotherapy and analgesics, have a role in pain relief.  
 
Unlike chemotherapy and hormonal treatments, the current bone-targeted therapies (e.g., 
bisphosphonates and denosumab) are mainly limited to delay the onset of skeletalrelated events (SRE) 
[5–7], without any improvement in survival. Similarly, externalbeam radiotherapy is an effective and 
costefficient treatment for metastatic bone pain, able to induce a quick symptomatic relief in 50–80% of 
patients, but without any evidence of increasing overall survival (OS) [8].  
 
The idea of using systemic radionuclide therapy targeting bone metastases results in an effective 
strategy able to deliver high doses of radiation to metastatic bone lesions, limiting the toxicity on healthy 
tissues [9–11]. During the last years, bone-targeting radiopharmaceuticals were represented by radioactive 
isotopes emitting b-particles, and lately by conversion electron emitters [12,13]. At present, only three 
compounds, 
89
Sr (approved in Europe for prostate cancer), 
153
Sm-lexidronam (153Sm- EDTMP; approved 
in Europe for osteoblastic metastases) and 186Re-etidronate (186Re- HEDP; approved in some European 
countries) have been available for pain relief secondary to skeletal metastases [14,15]. Unfortunately, the 
exposure of surrounding tissues to β and γ-emissions is associated with toxicities due to the relatively 
long range of the radiation. On the other hand, preliminary studies reported that radionuclides emitting α-
particles could represent a new approach in this setting [14]. α-Emitters are characterized by shorter range 
(<0.1 mm) and higher energy radiation than β-particles and γ-rays, according to low linear energy transfer 
(LET) radiation. In addition, tissue penetration with α-emitters accounts for a diameter of 2–10 cells, 
minimizing the damage to healthy hematopoietic tissue. Besides, due to the high LET radiation, α-
particles are evaluated as more lethal, inducing nonrepairable double-strand DNA breaks in adjacent 
tumor cells [16].  
 
Radium is a calcium mimetic bone seeker α-particle emitter able to focus on areas of increased bone 
turnover [14]. Presently, two forms of radium are available for clinical practice, Ra-223 and Ra-224. 
While Ra-224 has been used to treat only ankylosing spondylitis since 1999 [17], Ra-223 has been the 
first α-emitter radiopharmaceutical available for bone metastases treatment secondary to CRPC [18]. In 
addition, Ra-223 has been demonstrated to increase OS in a Phase III study involving CRPC patients with 
bone metastases, thus indicating that Ra-223 should not only be evaluated as a simple bone-seeking 
radiopharmaceutical, but also as a systemic strategy for these patients [19].  
 
The aim of this review article is to outline the clinical development of Ra-223, analyzing the rationale 
and evaluating the main toxicities associated with the therapy. In addition, we will discuss the appropriate 
patient profile that makes a patient suitable for treatment with Ra-223 in the context of the new 
therapeutic landscape.  
  
Radium-223  
Biophysical & preclinical studies  
Biophysical studies indicated that Ra-223 is a bone-seeking α-emitter agent that, due to the similar 
structure of calcium, is able to localize in the high calcium turnover, resorption, and formation areas such 
as bone metastasis [20]. These studies revealed that Ra-223 generates highly localized radiation in bone 
metastases of non-repairable double-stranded DNA breaks with minimal effects on normal tissues 
[19,21,22].  
 
Preliminary in vitro studies performed in cervical carcinoma cell line nhIK 3025 showed that, after the 
exposure to different doses of Ra-223, a radiation dose of 0.35 Gy induced a permanent stop in the G2 
Phase of the cell cycle [20].  
 
Subsequently, extensive preclinical studies conducted in animal models confirmed that Ra-223 acts as 
calcium mimetic naturally binding to the areas of bone formation [17,21,23–25].  
 
In particular, studies conducted on mice revealed stability and affinity for the α-emitter with osseous 
tissue, with the possibility of delivering the therapeutic radiation to bone metastases with acceptable bone 
marrow toxicity [25]. Following dosimetric evaluations indicated lower bone marrow toxicity for Ra-223 
versus mice treated with 89Sr, due to the lower uptake of Ra-223 in bone marrow (1%) after 3 days from 
the administration [25].  
 
Further studies conducted in a human breast cancer model (MT1) and animal models with bone cancer 
confirmed that, when Ra-223 is administered intravenously, it accumulates in the whole bone tissue, with 
a more intense concentration in high turnover areas as trabecular bone, fractures or metastases [21,23].  
Ra-223 & radioprotection  
Ra-223 has a half-life of 11.4 days, in between β-emitter treatments (89Sr: 50.5 days, 153Sm-EDTMP: 
1.9 days) [15], what is an advantage for its preparation, transportation and administration, being also short 
enough to avoid the generation of longlived radioactive waste in the hospital [20]. Most of the emitted 
energy is comprised of α (95.3%), β (3.6%) and γ (1.1%) particles or x-rays [20]. The short penetration of 
the α particles allows the use of standard radiation protection measures during shipping and 
administration; minimal radiation shielding is required.  
 
Alpha particles induce non-repairable double-stranded DNA breaks in adjacent tumor cells [16]. 
These particles are classified as high LET radiation with a low range of action (<100 m), minimizing 
damage to healthy tissue surrounding cancer cells. In contrast, β particles from therapeutic agents used for 
the palliation of pain (
89
Sr and 
153
Sm-EDTMP) produce low-LET radiation with a greater range of action 
and therefore myelosuppression [25]. Alpha particle emitters locate cellular destruction with high-dose 
radiation in a smaller area with minimal bone-marrow toxicity.  
 
The administered activity is absorbed by the bone in the initial hours after the intravenous 
administration (TABLE 1). The major route of elimination is intestinal [24], within the first week of 
treatment and to a lesser extent through the urine, contrary to other radionuclide therapies [21]. This 
seems to explain its main non-hematologic side effects, mainly digestive that, although manageable, 
limits its use in patients with fecal incontinence. The most frequently observed adverse reactions (≥10%) 
in patients receiving Ra-223 were diarrhea, nausea, vomiting and thrombocytopenia [26].  
 
  
Table 1. Calculated absorbed radiation dose to organs radium-223. 
Target organ 
 (Gy/MBq) 
α emission  
(Gy/MBq) 
β emission 
(Gy/MBq) 
γ emission  
(Gy/MBq) 
Total dose  
(Gy/MBq) 
     
Lower large intestine wall  0  0.04560  0.00085 0.04645 
Small intestine wall  0.00319  0.00360  0.00047  0.00726 
Stomach wall  0  0.00002  0.00012  0.00014 
Upper large intestine wall  0  0.03150  0.00082  0.03232 
Kidneys  0.00299  0.00011  0.00011  0.00320 
Liver  0.00279  0.00010  0.00008  0.00298 
Red marrow  0.13200  0.00642  0.00020  0.13879 
Osteogenic cells  1.14000  0.01490  0.00030  1.15206 
Urinary bladder wall  0.00371  0.00016 0.00016  0.00403 
Whole body  0.02220  0.00081  0.00012  0.02311 
     
 
Calculations of absorbed doses were performed using OLINDA/EXM (Organ Level 
INternal Dose Assessment/EXponentialModeling), a software based on the Medical 
Internal Radiation Dose algorithm, which is widely used for established beta- and 
gamma-emitting radionuclides. 
Gy: Grays; MBq: Megabecquerel. 
Regarding administration, it is performed by slow intravenous injection, and only by persons 
authorized to handle radiopharmaceuticals in designated clinical settings and after evaluation of the 
patient by a qualified physician. The volume to be administered should be calculated using the patient’s 
body weight (kg), dosage level (50 kBq/kg body weight), radioactivity concentration of the product (1000 
kBq/ml) at reference date (the reference date is stated on the vial and lead pot label) and decay correction 
(DK) factor to correct for physical decay of Ra-223 (a table of DK factors is provided with each vial as 
part of the booklet). The amount of radioactivity in the dispensed volume shall be confirmed by 
measurement in a properly calibrated activimeter. The total volume to be administered to a patient is 
calculated as follows: Volume to be administered (ml) = Body weight (kg) × activity (50 kBq/kg body 
weight)/DK factor × 1000 kBq/ml. No dose adjustment is considered necessary in patients with renal or 
hepatic impairment.  
 
Special warnings and precautions should be considered in patients with bone-marrow suppression. 
Therefore, hematological evaluation must be performed at baseline and prior to every dose of Ra-223. 
Before the first administration, the absolute neutrophil count should be ≥ 1.5 × 109/l, the platelet count ≥ 
100 × 109/l and hemoglobin ≥ 10.0 g/dl. Before subsequent administrations, the absolute neutrophil count 
should be ≥ 1.0 × 109/l and the platelet count ≥ 50 × 109/l.  
 
Spinal cord compression and bone fractures should be treated as clinically indicated before starting 
treatment with Ra-223. In patients treated with bisphosphonates and Ra-223, an increased risk for 
developing osteonecrosis of the jaw cannot be excluded. In the Phase III study, cases of osteonecrosis of 
the jaw were reported in 0.67% patients (4/600) in the Ra-223 arm compared to 0.33% patients (1/301) in 
the placebo arm. However, all patients with osteonecrosis of the jaw were also exposed to prior or 
concomitant bisphosphonates (e.g., zoledronic acid) and prior chemotherapy (e.g., docetaxel) [27]. No 
cases of Ra-223-induced cancer have been reported in clinical trials in follow-up of up to 3 years.  
 
The external radiation exposure associated with handling of patient doses is considerably lower in 
comparison to other radiopharmaceuticals for therapeutic purposes as the administered radioactivity will 
usually be below 8 MBq. Ra-223 contamination is highly unlikely [23]. This justifies the absence of 
patients’ contact restrictions with others after the treatment is administered.  
  
Review of Phase I–III clinical trials  
Phase I  
Based on the promising preclinical results, a Phase I dose escalating and safety study of Ra-223 was 
conducted in 25 subjects (15 metastatic CRPC and 10 metastatic breast cancers). The primary objective 
was to estimate the radiation dosimetry of a single dose of Ra-223. Patients were injected with 46–250 
kBq/kg intravenously and were followed for 8 weeks for adverse events (AEs) monitoring [28]. Some 
reversible myelosuppression occurred, with nadirs 2–4 weeks after injection and complete recovery 
during the follow-up period. The incidence and severity of all toxicities were directly related to the 
administered dose. The most common adverse reactions were diarrhea, bone pain (flare reaction 
included), asthenia, nausea and vomiting. Potentially serious side effects included diarrhea (one patient) 
and leucopenia (two patients). There were no hematological dose-limiting toxicities up to the maximum 
planned dose.  
 
The feasibility of repeating Ra-223 injections of two fixed dosage levels administered according to the 
schedule of 3- or 6-week intervals was evaluated in a Phase Ib study [29]. Six patients were recruited and 
received a total dose of 250 kBq/kg, two of them received injections of 125 kBq/kg at 6-week intervals, 
while four patients received 50 kBq/kg given five-times at 3-week intervals.  
 
Twenty out of the 31 patients included in the Phase I studies were still alive 1 year after the first 
injection of Ra- 223. No hematological, renal, gastrointestinal or hepatic late toxicities were reported. The 
consistent reduction in bone alkaline phosphatase (BAP) levels suggest that the most strongly targeted 
areas by Ra-223 would be the regions with an elevated bone metabolism, as is often seen in the zones of 
developing skeletal metastases [29]. The decrease of the serum BAP, as surrogate marker, and the relief 
of secondary pain in bone metastases encouraged to perform the following Phase II studies.  
Phase II  
The placebo-controlled Phase II study BC1-02 was conducted in patients with symptomatic CRPC 
[30]. Patients with bone pain needing external beam radiotherapy were assigned to four intravenous 
injections of Ra-223 (50 kBq/kg) or placebo, every 4 weeks for 12 weeks. The primary endpoints were 
the mean change in BAP from baseline to 4 weeks after the last injection and time to occurrence of SREs. 
Secondary endpoints included evaluation of safety, serum markers of bone turnover, prostate specific 
antigen (PSA) and OS. No differences in toxicity, except constipation, were reported, and hematological 
toxic effects did not differ significantly between the two groups, with no patients discontinuing Ra-223 
because of treatment toxicity. Similar to Phase I trials, the results reported a decrease in PSA of over 50% 
from baseline in patients treated with Ra-223. Median time to PSA progression was 26 weeks versus 8 
weeks for Ra-223 versus placebo, and median time to first SRE was 14 weeks in the Ra-223 arm versus 
11 weeks in the placebo arm (p = 0.257), with a hazard ratio (HR) of 1.75 (95% CI: 0.96–3.19; p = 0.065) 
favoring Ra-223 when adjusted for baseline covariates. A significant OS benefit was reported, although, 
bias may exist with regard to these data due to the relatively small number of included patients (64 in 
total) and the concomitant treatment with steroids or antiandrogens in these patients [30].  
 
The BC1-03 study was a double-blinded, dose-ranging, randomized study comparing the palliative 
effects of four different single dose levels of Ra-223 (5, 25, 50 or 100 kBq/kg) in progressive metastatic 
CRPC patients with bone metastases and pain [18]. The primary endpoint was the change in ‘pain index’ 
(derived from a combination of the visual analog scale and analgesic consumption categorized according 
to the WHO analgesic use score at weeks 2, 4, 8, 12 and 16). Secondary endpoints included change from 
baseline in the brief pain inventory severity index and functional index, OS, duration of pain relief, 
relative change in bone BAP and PSA and assessment of AEs. One hundred patients were randomized. A 
statistically significant dose response, for pain relief and stable analgesic use, occurred at week 2 (p = 
0.035). At week 8, there were 40, 63, 56 and 71% patients with pain relief in the 5, 25, 50 and 100 kBq/kg 
groups, respectively [18]. BAP decrease over 50% from baseline occurred in all groups, although it was 
only statistically significant in the 100 kBq/kg dose group at weeks 4 and 8. A well-tolerated safety 
profile was observed. Remarkably, there may have been a problem with dropout bias, since 17 patients 
dropped out by week 8, and there was an important difference in dropouts in the low versus high-dose 
arms (eleven vs six patients).  
 
The BC1-04 was a multicenter double-blinded, randomized, dose-finding study in patients with CRPC 
and bone metastases. Three dose levels of Ra-223 (25, 50 and 80 kBq/kg) were compared, every 6 weeks 
for 12 weeks (three total doses). The primary end point was PSA response (≥ 50% decline from baseline); 
bone markers, SREs, AEs, and survival were secondary endpoints [31]. A total of 121 patients were 
randomized. Primary endpoint was achieved, showing a dose-dependent effect for the three dose levels 
25, 50 and 80 kBq/kg, respectively. Again, the good safety profile of Ra-223 was confirmed. The most 
frequent AEs were nausea, vomiting and diarrhea and two cases of grade 3–4 thrombocytopenia were 
observed [31]. Normalization of BAP was associated with a significantly better survival, compared with 
those patients who did not achieve BAP normalization. Observed data from BC1-04 study supported the 
optimal therapeutic dose level of 50 kBq/kg for a subsequent Phase III trial.  
Phase III  
The ALSYMPCA trial was an international, randomized, double- blinded, placebo-controlled Phase 
III study conducted in men with symptomatic metastatic CRPC [19,32,33]. Inclusion criteria included 
symptomatic CRPC, two or more bone metastases, no known visceral metastases and either 
docetaxelpretreated patients or those that were unfit for docetaxel. Patients were randomized 2:1 to 
receive Ra-223 injections at 50 kBq/kg plus best standard of care versus placebo plus best standard of 
care. ‘Best standard of care’ included secondary hormonal therapies or external-beam radiotherapy, but 
not cytotoxic chemotherapy or radioisotopes. Subjects were stratified according to total BAP, 
bisphosphonate use and prior docetaxel treatment. Primary endpoint was OS, and secondary endpoints 
were time to first SRE, time to total BAP progression, total BAP response, total BAP normalization, time 
to PSA progression, safety and quality of life. The trial enrolled 922 patients (Ra-223, n = 614; placebo, n 
= 307). Patients enrolled in the study received up to six intravenous injections of Ra-223 or placebo, 
given at 4-week intervals [19,32,33].  
 
The trial was stopped based on the recommendation of an independent data monitoring committee, 
due to early evidence of benefit in terms of OS (with crossed predetermined boundary). Ra-223 
significantly improved OS in patients with CRPC and bone metastases compared with placebo (p < 0.001; 
HR = 0.70; 95%; CI: 0.58–0.83; median OS 14.9 months versus 11.3 months, respectively). A beneficial 
effect was also shown in all subgroups except for patients with Eastern Cooperative Oncology Group 
score (ECOG)-PS 2 or superior, which did not reach statistical significance. Time to first SRE was 
significantly prolonged (median 15.6 months versus 9.8 months, respectively; HR = 0.66; 95% CI: 0.52–
0.83; p < 0.001) [17,19]. In addition, there was a meaningful improvement in the quality of life, evaluated 
with functional assessment scale – prostate subscale scores; mainly for pain, physical, social/familial, 
emotional and functional well being subscales [19,33].  
 
No differences in severe side effects (grade 3–4) were observed between Ra-223 and placebo groups. 
Anemia incidence was identical in both arms (13%), as well as for neutropenia (3 vs 1%), diarrhea and 
vomiting (2% in both arms). Likewise, toxicity of any grade (grade 1–4), showed only small differences 
in incidence of diarrhea (25% of patients with Ra-223 vs 15% in patients with placebo) and 
thrombocytopenia (12 vs 6%, respectively) [19,33].  
 
This study not only achieved an improvement in OS, but also in all secondary endpoints including 
time to first SRE. As of note, the Ra-223 arm was compared to standard treatment at physician’s choice 
and, therefore, these interesting results may be applicable to routine clinical practice. This is particularly 
interesting, since other palliative therapies, such as radiotherapy, were considered as a prohibited 
concomitant medication in the Phase III abiraterone trial. Nonetheless, there is an important limiting 
factor in the ALSYMPCA trial: visceral metastases were an exclusion criterion, and this circumstance 
may appear in up to 25% of patients with CRPC [19,34].  
 
The safety results within approximately 1.5 years after treatment concluded that the incidence of 
myelosuppression among Ra-223 patients remained low and that there were no additional safety issues of 
acute myelogenous leukemia, myelodysplastic syndrome, aplastic anemia or primary bone cancer. Thus, 
findings from this long-term follow-up data support further evaluation of combining Ra-223 with other 
agents for the treatment of patients with CRPC and symptomatic bone metastases [27].  
Alpha emitter for CRPC patients: new opportunities  
Since Ra-223 has a mechanism of action completely different from traditional systemic therapies 
already available in CRPC treatment, such as chemotherapy (docetaxel and cabazitaxel) and hormone 
therapy (abiraterone and enzalutamide), its introduction in clinical practice could be considered a new 
therapeutic paradigm [31]. Therefore, a number of new issues are emerging. First, how can those patients 
be identified who should be treated with Ra-223 and, subsequently, what are the best tools for a correct 
follow-up of treated patients? And finally, what opportunities are open for future studies, such as 
combination with other drugs in the next future.  
 
Once the main preclinical and clinical data are reviewed, it can be concluded that main strengths of 
Ra-223 include: 
 
 It has a new and challenging mode of action and is clearly a major advance over first-generation 
radiopharmaceuticals. 
 It is well tolerated, with easy-to-handle side effects, and with no renal or liver toxicity. 
 There is a wide population that could benefit from Ra-223, since most of the patients in routine 
clinical practice fulfill the ALSIMPCA eligibility criteria. 
 It improves survival as well as quality of life, pain control and other secondary endpoints.  
 The medication dosage is comfortable; administration is simple, not time consuming and suitable for 
most patients. .  
 Results can be generalized since ‘standard of care’ is a very wide option, including also 
radiotherapy.  
 
With regard to weaknesses, it could be pointed that the likely ordering of treatment lines in this setting 
of patients is still unclear. Patients who had progressed after docetaxel treatment were eligible in the 
ALSYMPCA trial, and even this subgroup benefited from Ra-223. There are several potential treatment 
choices for these patients before switching to Ra-223. If the ‘switch’ is made while there are still 
alternative options, it brings up the question of whether chemotherapy is a comparator to Ra-223 in some 
situations.  
Patient profile  
With the purpose of describing the appropriate patient profile for Ra-223, a comparison of the baseline 
characteristics included in the Phase III studies of cabazitaxel, abiraterone and enzalutamide showing 
survival benefit in metastatic CPRC patients that had progressed after docetaxel treatment has been 
performed (TABLE 2) [33–36]. These results are only descriptive without any comparative aim, since the 
role of each only can be defined in terms of current clinical data and practice. These data are analyzed 
taking into consideration the efficacy reported in the subgroup analysis of every single study, keeping in 
mind that all these analyses were not powered to draft any conclusion.  
  
Table 2. Baseline characteristics of patients included in the Phase III trials with radium-223, cabazitaxel, abiraterone and 
enzalutamide 
 Ra-223 [33]  Cabazitaxel [34]  Abiraterone [35]  Enzalutamide [36] 
     
PS (ECOG) = 2 (%)  12†  7  10  8.5 
Visceral disease (%)  –  25  18  23.2 
Bone lesions >20 (%)  41  –  –  37.8 
≥ 2 previous chemo regimens (%)  –  31  30  27 
PD ≤ 3 months post-docetaxel (%)  –  72  30  – 
PSA levels (ng/ml), median (min-max) 146  
(3.8–6026) 
143.9  
(51.1–416) 
128.8  
(0.4–9253) 
107.7 
 (0.2–11794.1) 
     
 
†Patients with ECOG ‡2 are included in this subgroup. 
PD: Progressive disease. 
An important exclusion criterion of the Ra-223 Phase III study was the presence of visceral 
metastases, although patients with limited lymph nodal dissemination were included [33]. On the 
contrary, patients with visceral metastases were enrolled in the studies with cabazitaxel (TROPIC), 
abiraterone (COU-AA-301) and enzalutamide (AFFIRM). Therefore, these drugs should be preferred in 
this setting. In particular, cabazitaxel seems to be the most indicated drug, because up to 25% patients 
with visceral metastases were included [34] in this study and a subgroup analysis presented in 2012 
suggested a benefit for both patients with visceral metastases (OS HR = 0.88; 95% CI: 0.64–1.22) [37]. 
Enzalutamide, in the subgroup analysis of the AFFIRM study, seems to suggest a lower activity (HR = 
0.78; 95% CI: 0.56–1.09) [36]. Abiraterone, in the subset with visceral disease, achieved a median OS of 
12.9 months compared with 8.3 months with placebo. Although there was a similar HR for superior 
survival with abiraterone in the visceral disease group, this difference did not reach statistical significance 
due to the much smaller sample size (HR = 0.79; 95% CI: 0.60–1.05; p = 0.102). The magnitude of the 
median survival benefit with abiraterone was similar in patients with visceral disease at baseline and those 
without visceral disease. Treatment with abiraterone significantly reduced the risk of radiographic 
progression or death by 40 and 32% in patients with visceral disease or without visceral disease, 
respectively [38].  
 
Use of Ra-223 is limited to all setting of patients with symptomatic bone metastases without visceral 
disease independently of the previous treatment with docetaxel. In fact, the ALSYMPCA study enrolled 
the following three groups: patients pretreated with docetaxel, patients noneligible to docetaxel or those 
refusing docetaxel therapy [33]. Analysis of subgroups reported that survival benefit is similar whether or 
not patients had received docetaxel (HR = 0.71 vs 0.74) [33].  
 
With regard to the benefit of using Ra-223 after other therapies, currently, it is not possible to draft 
any conclusions about docetaxel-refractory patients, candidates to cabazitaxel, or patients previously 
treated with Sipuleucel-T and abiraterone or treated with two or more lines of chemotherapy. There are 
only available data for patients with a rapid progression to chemotherapy treated with cabazitaxel and 
abiraterone. In fact, the two Phase III studies, TROPIC and COU-AA-301, recruited also patients 
progressing less than 3 months from docetaxel [34,35].  
 
Regarding performance status, all the studies included patients with ECOG 2. Subgroup analyses 
reported that the four drugs seem to induce a lower efficacy in this setting [33,34,36,38]. However, these 
data should be considered with caution, because the number of patients included in every single subgroup 
is low. With regard to pain at baseline, it is difficult to draw any conclusion, because of the different 
scales used and the nonavailability of full data for every single Phase III study. All analyzed Phase III 
studies enrolled patients with similar characteristics in terms of initial PSA level (TABLE 2). Subgroup 
analyses of both studies for abiraterone and enzalutamide suggest that the drugs induce benefit 
independently whether PSA levels are above or under the median value at baseline [36,38]. On the 
contrary, cabazitaxel seems to induce benefit only in the subset of patients where PSA is rising at baseline 
[37].   
The analysis regarding patients treated with bisphosphonates is reported only for the ALSYMPCA 
study. The benefit in OS induced by Ra-223 is also similar, independent of bisphosphonates treatment 
(HR = 0.7 vs 0.74) [27].  
 
Patient preference is a key issue that should be evaluated prior to any drug selection; the treatment of 
choice should be selected after sharing the main information with the patient, and depending not only on 
survival and disease control, but rather on improvement in symptomatology and quality of life.  
Toxicity profile  
TABLE 3 summarizes the main toxicities observed in the Phase III trial conducted with Ra-223, 
cabazitaxel, abiraterone and enzalutamide.  
Table 3. Incidence (%) of main toxicities (grade 3–4) observed with radium-223, cabazitaxel, abiraterone and enzalutamide. 
 Radium-223 [27] Cabazitaxel [34] Abiraterone [35] Enzalutamide [36] 
     
Anemia  13  11  7  – 
Neutropenia  3  82  <1  – 
Neutropenic fever  –  8  – – 
Thrombocytopenia  6  4  <2  – 
Diarrhea  2  6  1  1 
Nausea  2  2  3  – 
Vomiting  2  2  3  – 
Fatigue  –  5  9  6 
Hot flashes  –  –  –  0 
Hypertension  –  –  1  – 
     
 
Data extracted from the main Phase III studies [27,34–36]. 
Ra-223 seems to induce slightly bone-marrow and gastrointestinal toxicities [27]. Diarrhea must be 
taken into consideration, since fecal excretion is the major route of elimination of the α-emitter from the 
body and, consequently, fecal incontinence may compromise the metabolism of the radiopharmaceutical 
[27].  
 
Cabazitaxel displays a significantly higher hematological toxicity (neutropenia, neutropenic fever, 
anemia and thrombocytopenia). Furthermore, cabazitaxel induced toxic deaths in 5% of patients [34]. 
These data suggest that in patients with preexisting bone marrow toxicities, cabazitaxel should be used 
with caution, with a strict hematologic toxicity follow-up, and prophylactic G-CSF could be 
recommended.  
 
Abiraterone presents an excellent tolerance profile, although it needs administration of prednisone in 
order to prevent the toxicity derived from the excess of mineralocorticoids due to the CYP17 blockade 
[35]. Less than 2% of patients presented neutropenia or severe thrombocytopenia, and 7% of patients 
presented grade 4 anemia. Due to the effect of mineralocorticoid, 31% of patients presented edema/fluid 
retention (less than 3% severe), 17% hypokalemia (less 4% severe) and 10% hypertension (1% severe). 
Overall, abnormalities in liver function tests occurred at a similar frequency in the abiraterone acetate and 
placebo groups, including changes of any grade in liver function tests (10 and 8%, respectively) and grade 
3 or 4 changes in liver function tests (3.5 and 3.0%) [35]. 
  
Finally, enzalutamide showed a toxicity profile similar to placebo; the main side effects of 
enzalutamide were fatigue (6%, grade 3), diarrhea (1%, grade 3), hot flushes (20%, all grade 1–2), bone 
pain (1%, grade 3) and headache (<1%, severe); cardiac events were observed in 6% of patients with 
enzalutamide versus 8% in the placebo arm, with a slightly higher hypertension incidence in the 
experimental arm (6.6 vs 3.3%). No evidence of metabolic syndrome was observed [38]. It is worth 
mentioning that the AFFIRM study was amended, excluding patients with seizures due to a supposed 
induction of sudden attack by enzalutamide [36].  
New methods of evaluation  
In addition to providing clinical information, studies conducted with Ra-223 also provided 
information regarding new possible methods of biochemical (BAP) and radiological follow-up Positron 
Emission Tomography (PET) for patients on therapy.  
Bone alkaline phosphatase  
A frequent diagnostic open issue in the field of prostate cancer is related to the directional changes of 
PSA levels, the most frequently altered biomarker in the disease.  
 
It is known that PSA can reflect the burden of CRPC [39], and consequently, monitoring PSA changes 
could support in detecting reduction in disease burden after treatment. However, the interpretation of PSA 
changes seems to be affected by several important caveats, as those correlated to the evaluation of 
response after immunological or cytostatic treatment [40]. In this regard, the Prostate Cancer Working 
Group guidelines do not recognize PSA changes as the sole endpoint to decide change of therapy or to 
declare treatment failure, so that further biomarkers are needed [40].  
 
Investigations on Ra-223 conducted since Phase I study revealed that its activity was related to the 
reduction of BAP [41,42]. According to investigators of ALSYMPCA study, BAP appeared as a more 
sensible biomarker than the classic PSA; therefore, BAP was evaluated as secondary endpoint through the 
following three parameters: time to total BAP progression, total BAP response and total BAP 
normalization [27]. Future studies could confirm the important role of BAP in the follow-up of patients 
with bone metastases treated with the other drugs for prostate cancer. More evidence is needed but, with 
the results obtained from the ALSYMPCA trial, it could be recommended to perform BAP assessments 
and take into consideration with both imaging procedures and PSA. A predictive model including BAP, 
PSA and eventually circulating tumoral cells may be of interest in this set of patients; further prospective 
studies are a medical need.  
18
F-fluoride PET  
A second diagnostic point emerging from Ra-223 studies is related to radiological imaging monitoring 
of bone metastases. Bone metastases are difficult to monitor during treatment, and the imaging modalities 
used to assess disease in bone have not been standardized. The 99mTc-methylene diphosphonate 
scintigraphy is a traditional diagnostic therapy with well-known limits of sensitivity. A qualitative 
assessment of conventional bone scintigraphy with 99mTc methylene diphosphonate is perceived as an 
insensitive method for monitoring the treatment response of bone metastases.  
 
18
F-fluoride PET/CT is a highly sensitive and specific modality for detection of bone metastases in 
patients with high-risk prostate cancer. It is more specific than 
18
F-fluoride PET alone and more sensitive 
and specific than single-photon emission computed tomography (SPECT) and bone scintigraphy. 
Detection of bone metastases is improved by SPECT compared with planar bone scintigraphy, and by 
18
F-fluoride PET compared with SPECT [43]. Recently, a pilot study was conducted to evaluate the 
efficacy of early treatment response to Ra-223 with 
18
F-fluoride PET [44]. This study showed the 
feasibility of measuring variation in the uptake of 
18
F-fluoride with PET during the treatment with Ra-223 
and suggested that the semi-quantitative 
18
F-fluoride PET is more accurate than the qualitative 
comparison of scans in assessing response in bone metastases. In fact, a correlation with the PSA 
response and BAP activity was observed, offering a potential imaging biomarker for monitoring treatment 
response in bone metastases following treatment with Ra-223. Studies with more patients are needed to 
establish a formal method of analysis and provide better diagnostic and prognostic information.  
 
Nevertheless, the available data with regard to the use of 
18
F-fluoride PET in this setting is very 
limited so far. The study performed in patients with high-risk prostate cancer included a very small 
number of patients, and therefore limitations of the data are clearly present. Thus, PET would be 
recommended to be added to the suggested algorithm, including PSA, BAP and imaging tests.  
Ongoing & future studies  
The achieved outcomes so far with Ra-223 encourage fulfilling further steps in the studies to better 
understand the activity of this radiopharmaceutical and to try to extend its benefit. Currently, clinical 
development is addressed in the following directions: 
 
 Continue testing its efficacy and adverse effects on expanded access studies. 
 Explore different administration schedules and their use in different patient populations. 
 Combination with other agents.  
 
Two prospective, interventional, open-label, multicenter early access program studies are ongoing 
[45,46]. Both are being conducted in CRPC patients diagnosed with bone metastases, with the collection 
of additional short- and long-term safety data of Ra-223. Inclusion and exclusion criteria for patients are 
similar to those of the Phase III trial ALSYMPCA.  
 
As far as different schedule of treatment is concerned, data from reported Phase I and II studies are 
promising with regard to safety and tolerability, with studying Ra-223 at the dose of 50 kBq/kg 
administered at 4 weekly intervals [31,32]. Therefore, both dose and schedule were chosen for the 
experimental arm in the ALSYMPCA trial. However, a dose response in the BAP decrease according to 
different doses of Ra-223 has been observed, and different intervals between administrations have been 
also studied (3–4 weeks) [27,33,34]. This implicates the need to explore new schedules based on different 
dose escalations and treatment duration. In addition, we need to determine the optimal interval between 
doses (3, 4 or 6 weeks) and the total number of administrations that are associated with an optimum 
benefit.  
 
Similarly, as with other drugs (e.g., docetaxel), another interesting question is, whether there is a role 
for re-treatment with Ra-223 in patients who benefit from the first treatment.  
 
Due to the singular mechanism of action, it was reported that there exists a strong rationale for the 
combination of Ra-223 with the main antitumor drugs already approved for the treatment of CRPC 
patients, such as docetaxel, cabazitaxel, abiraterone acetate and enzalutamide. These agents, in fact, could 
complement the action of Ra-223, allowing its use in patients with bone metastases.  
 
Concerning the association with chemotherapy, a Phase I–II study is trying to establish the 
recommended dose of Ra-223 to be used in combination with docetaxel in patients with metastatic CRPC, 
and to investigate the safety and efficacy of this combination [47]. The first step of the study concluded 
that dose regimen of Ra-223 (50 kBq/kg q 6 weeks × 5) combined with docetaxel (60 g/m
2
 q 3 weeks × 
10) is safe, allowing to proceed into the following Phase IIa, in which this combination will be compared 
with docetaxel (75 mg/m
2
) every 3 weeks.  
  
Combination studies with either abiraterone or enzalutamide are encouraging on account of their very 
low toxicity profile, but there data are not yet available to support either of these combinations. These 
combinations are being tested currently in several trials; two of them are particularly interesting:  
 
A Phase III, double-blinded, placebo-controlled, multinational trial will randomize 800 patients with 
asymptomatic or mildly symptomatic, chemotherapy-naïve, bone-predominant metastatic CRPC to 
receive Ra-223 (50 kBq/kg iv.) every 4 weeks for six cycles or Ra-223 plus abiraterone, followed by 
abiraterone until a symptomatic skeletal event or death occurs [48]. The primary objective is progression-
free survival (PFS). Secondary endpoints include OS, time to pain progression, time to opiate use for 
cancer pain, time to cytotoxic chemotherapy, radiographic progression-free survival and acute and long-
term safety. This trial is currently recruiting participants.  
 
On the other hand, a randomized Phase III trial comparing enzalutamide versus Ra-223 and 
enzalutamide in asymptomatic or mildly symptomatic patients metastatic to the bone will recruit 560 
patients. The objective of this trial is to assess if upfront combination of enzalutamide and Ra-223 
improves radiological progression-free survival compared to single agent enzalutamide [49].  
Expert commentary  
The knowledge about prostate cancer therapeutics and prognostic– predictive factors has been 
increasing in the recent years, and several new drugs have been added to the previously available 
treatments. Nevertheless, there is not a clear algorithm about treatment line choices, and there is no solid 
data yet to strongly recommend the procedures to be performed in order to evaluate disease progression.  
 
ALSYMPCA trial aimed to include a very wide population to get applicable results to routine clinical 
practice, and all subgroups achieved clinical benefit with Ra-223, including the group of patients that had 
received prior docetaxel. Docetaxel is still a treatment option in this kind of patients, despite many 
physicians trying to avoid chemotherapy in patients who are only presenting bone metastases.  
Five-year view  
Probably the key results will be given as soon as there is more data from the trials combining Ra-223 
and abiraterone or enzalutamide. Also, a trial testing the combination of Ra-223 plus docetaxel in patients 
with both bone and visceral metastases could clarify some aspects that are still unanswered. How to deal 
with those patients with bone and visceral disease? Which would be the best treatment sequence? The 
more information is got, the more questions appear.  
 
Future research will be necessary to clarify further benefits associated with different treatment 
schedules (e.g., different number of doses, frequency of administration) or the possibility of re-treating 
patients who previously and successfully responded to this therapy, but probably Ra-223 will be a 
standard combined with other treatments, as other chemotherapeutic or hormonal agents in order to 
expand its benefit in CRPC patients with bone metastases.  
Conclusions  
The hypothesis that α-emitters could represent a new paradigm in the treatment of prostate cancer has 
been confirmed by the use of Ra-223. Ra-223 induced a significant survival benefit, delaying the onset of 
SRE and showing an acceptable bone marrow safety profile, and all these achievements had never been 
seen described using the previously available radiopharmaceuticals. In particular, its survival benefit 
appears comparable to that described with chemotherapeutic and hormonal agents in a similar subset of 
patients. New opportunities have emerged after the study with Ra-223, such as new biochemical markers 
and new imaging methods.  
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